A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers

Smoking Cessation Clinical Trial

Official title:

Repeat-Dose Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03303911
• Other study ID #: ACH-CYT-02
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: October 6, 2017
• Est. completion date: October 5, 2018

Study information

• Verified date: October 2019
• Source: Achieve Life Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of this study are:

• To evaluate the pharmacokinetic (PK) parameters during repeat dosing of 1.5 mg or 3.0 mg cytisine when administered as the commercial 25-day schedule.

• To evaluate the pharmacodynamic (PD) effects (e.g., reduction in smoking) with repeat dosing of 1.5 mg or 3.0 mg cytisine when administered as the commercial 25-day schedule.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 26
• Est. completion date: October 5, 2018
• Est. primary completion date: October 5, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Regular moderate cigarette smokers (minimum 10 cigarettes per day) who want to stop smoking.

2. Urine cotinine >500 ng/mL.

3. Expired air carbon monoxide (CO) > 11 parts per million (no cigarette 1 hour before test).

4. Healthy males and females 18-65+ years of age.

1. If a female subject of child bearing potential, a negative pregnancy test at screening and admission and willing to use an effective method of contraception (unless of non-childbearing potential or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of cytisine.

2. If a female subject of non-child bearing potential, a negative pregnancy test at screening and admission. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy). Menopausal status will be confirmed by demonstrating at screening that levels of follicle stimulating hormone (FSH) fall within the respective pathology reference range. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at Investigator's discretion following consultation with the Sponsor.

3. If a male subject, willing to use an effective method of contraception (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of cytisine.

5. Subject with no clinically significant abnormal serum biochemistry, haematology and urine examination values within 28 days before the first dose of cytisine.

6. Subject with negative urinary drugs of abuse screen, determined within 28 days before the first dose of cytisine (a positive alcohol result may be repeated at Investigator's discretion).

7. Subject with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (Hep B) and hepatitis C virus antibody (Hep C) results.

8. Subject with no clinically significant abnormalities in 12-lead ECG determined after minimum of 5 minutes in supine position within 28 days before the first dose of cytisine.

9. Subject with no clinically significant abnormalities in vital signs (systolic blood pressure between 90-150 mmHg (age 18-65) and 90-160 mmHg (age >65), diastolic blood pressure (DBP) between 50 and 90 mmHg, and pulse rate (PR) between 40 110 bpm, measured on the dominant arm after minimum of 5 minutes in supine position) determined within 28 days before first dose of cytisine.

10. Subject must be available to complete the study (including in-clinic stays and post study follow-up) and comply with study restrictions.

11. Subject must provide written informed consent to participate in the study.

Exclusion Criteria:

1. Treatment with smoking cessation medications (bupropion, varenicline, any nicotine replacement therapy) within 8 weeks of first dose of cytisine.

2. Use of other forms of nicotine (e-cigarettes, smokeless tobacco) within 8 weeks of first dose of cytisine or are planning to use these products during study.

3. Known hypersensitivity/allergy reaction to varenicline, other cytisine-derivatives or any of the excipients in the Tabex formulation.

4. History of severe hypersensitivity reactions to any other drugs.

5. Current treatment with antihypertensive medicinal products, statins, tuberculostatics, cholinomimetics or anticholinesterase medicinal products.

6. History of any medical condition (e.g. gastrointestinal, renal or hepatic) or surgical condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion).

7. Female subjects who are breast feeding.

8. Difficulty in donating blood on either arm or known history.

9. History of alcoholism or drug abuse within last 2 years.

10. Use of non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days (or 5 half-lives, whichever is longer) prior to the first dose of cytisine, unless in the opinion of the Principal Investigator the medication will not interfere with the study procedures or compromise subject safety.

11. Participated in any investigational drug clinical trial within the previous 3 months or a marketed drug trial within the previous 30 days prior to randomisation on Day 1.

12. Donation of 450 mL or more blood or had history of significant blood loss due to any reason or had plasmapheresis within 3 months before the first dose of cytisine.

13. Inability to communicate well with Principal Investigator or designees (i.e., language problem, poor mental development or impaired cerebral function).

14. Any other condition that the Principal Investigator considers making the subject unsuitable for this study.

Related Conditions & MeSH terms

• Smoking Cessation

Intervention

Drug:
• Cytisine
film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose

Locations

Country	Name	City	State
United Kingdom	Simbec Research Ltd	Cardiff

Sponsors (1)

Lead Sponsor	Collaborator
Achieve Life Sciences

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Observed Plasma Concentration (Cmax)		after the first dose and the last dose on Day 1; after the last dose on Days 2, 3, 12, 16, 20, 24; and after the morning dose on Day 25
Primary	Time of Occurrence of Cmax (Tmax)		after the first dose and the last dose on Day 1; after the last dose on Days 2, 3, 12, 16, 20, 24; and after the morning dose on Day 25
Primary	Minimum Observed Plasma Concentration (Cmin)		after the first dose on Days 4, 13, 17, 21 and 25
Primary	Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Sampling Time (AUC0-t)		after the administration of the final dose of cytisine on Day 25
Primary	Total AUC From Time Zero to Infinity (AUC0-8)		after the administration of the final dose of cytisine on Day 25
Primary	Residual Area or Percentage of Extrapolated Part for the Calculation of AUC0-8 (%AUC)		after the administration of the final dose of cytisine on Day 25
Primary	Apparent Terminal Elimination Rate Constant (?z)		after the administration of the final dose of cytisine on Day 25
Primary	Apparent Terminal Elimination Half-Life (t1/2)		after the administration of the final dose of cytisine on Day 25
Primary	Number of Cigarettes Smoked Daily During Treatment and at Day 26		Day 1 through Day 26
Primary	Change From Baseline in Number of Cigarettes Smoked Daily up to Day 26		Baseline, Day 1 through Day 26
Primary	Change From Baseline in Expired Air CO up to Day 26		Baseline, Days 4, 13, 17, 21, 26
Primary	Number of Participants Who Ceased or Continued Smoking on Day 26	A status of "ceased smoking" is defined as not having smoked any cigarettes for the past 24 hours on Day 26 and having an expired CO level <10 ppm on Day 26.	Day 26
Primary	Change From Baseline Over Time in Urine Cotinine		Baseline, Days 4, 13, 17, 21, 26
Primary	Change From Baseline Over Time in TCQ-SF Score: Emotionality	The TCQ-SF is a 12-item questionnaire that assesses 4 components of tobacco craving: emotionality (3 items), expectancy (3 items), compulsivity (3 items) and purposefulness (3 items). Responses to each item are scored from 1 (strongly disagree) through 7 (strongly disagree). Component scores are defined as the sum of the scores within each component. The total score is defined as the sum of the 4 component scores. Emotionality scores may range from 3 to 21, with lower scores indicating weaker emotional signs of tobacco craving.	Baseline (Day -1), Days 4, 13, 17, 21, 26
Primary	Change From Baseline Over Time in TCQ-SF Score: Expectancy	The TCQ-SF is a 12-item questionnaire that assesses 4 components of tobacco craving: emotionality (3 items), expectancy (3 items), compulsivity (3 items) and purposefulness (3 items). Responses to each item are scored from 1 (strongly disagree) through 7 (strongly disagree). Component scores are defined as the sum of the scores within each component. The total score is defined as the sum of the 4 component scores. Expectancy scores may range from 3 to 21, with lower scores indicating less positive expectations about smoking.	Baseline (Day -1), Days 4, 13, 17, 21, 26
Primary	Change From Baseline Over Time in TCQ-SF Score: Compulsivity	The TCQ-SF is a 12-item questionnaire that assesses 4 components of tobacco craving: emotionality (3 items), expectancy (3 items), compulsivity (3 items) and purposefulness (3 items). Responses to each item are scored from 1 (strongly disagree) through 7 (strongly agree). Component scores are defined as the sum of the scores within each component. The total score is defined as the sum of the 4 component scores. Compulsivity scores may range from 3 to 21, with lower scores indicating compulsion to smoke was a lesser component of tobacco craving.	Baseline (Day -1), Days 4, 13, 17, 21, 26
Primary	Change From Baseline Over Time in TCQ-SF Score: Purposefulness	The TCQ-SF is a 12-item questionnaire that assesses 4 components of tobacco craving: emotionality (3 items), expectancy (3 items), compulsivity (3 items) and purposefulness (3 items). Responses to each item are scored from 1 (strongly disagree) through 7 (strongly disagree). Component scores are defined as the sum of the scores within each component. The total score is defined as the sum of the 4 component scores. Purposefulness scores may range from 3 to 21, with lower scores indicating stronger ability to not smoke.	Baseline (Day -1), Days 4, 13, 17, 21, 26
Primary	Change From Baseline Over Time in TCQ-SF Score: Total Score	The TCQ-SF is a 12-item questionnaire that assesses 4 components of tobacco craving: emotionality (3 items), expectancy (3 items), compulsivity (3 items) and purposefulness (3 items). Responses to each item are scored from 1 (strongly disagree) through 7 (strongly disagree). Component scores are defined as the sum of the scores within each component. The total score is defined as the sum of the 4 component scores. Total scores may range from 12 to 84, with lower scores indicating lower tobacco craving.	Baseline (Day -1), Days 4, 13, 17, 21, 26
Secondary	Cytisine Amount Excreted in Urine Over Time (Ae0-24h)		Day 1 (6 times daily at 2-hour intervals); after the administration of the single dose of cytisine on Day 25
Secondary	Percent of Drug Excreted in Urine (Ae%)		Day 1 (6 times daily at 2-hour intervals); after the administration of the single dose of cytisine on Day 25
Secondary	Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuation of Study Drug Due to TEAEs	An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) is defined as an AE that results in any of the following: results in death; is life-threatening; requires hospitalisation or prolongs existing inpatient's hospitalisation; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medical event which requires medical intervention to prevent any of the above outcomes.TEAEs are defined as AEs not present prior to first administration of investigational product, or AEs present before first administration of investigational product that worsen after the participant receives the first dose of investigational product.	From first dose of study drug through Day 26 plus 6-8 days
Secondary	Number of Participants With Clinically Significant Values in Biochemistry, Hematology, and Urinalysis		up to Day 26
Secondary	Number of Participants With Clinically Significant Values in Vital Signs and Physical Examinations		up to Day 26
Secondary	Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Parameters		up to Day 26
Secondary	Number of Participants With Holter ECG Outlier Values	Based on the mean of the triplicate recordings at each time point. Increase (?)/decrease (?) calculated from Baseline (BL), defined as the mean of all recordings taken prior to dosing on Day 1 (i.e. -30 minutes and -15 minutes). A participant with multiple occurrences of an event is counted only once per event.	on Day 1 and Day 25 at 30 and 15 minutes prior to the first dose and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours post dose